Mechanism and prevention strategy of a bidirectional relationship between heart failure and cancer (Review)
- Authors:
- He Cai
- Hongbo Men
- Pengyu Cao
- Yang Zheng
-
Affiliations: Cardiovascular Center, The First Hospital of Jilin University, Jilin University, Changchun, Jilin 130021, P.R. China - Published online on: October 20, 2021 https://doi.org/10.3892/etm.2021.10898
- Article Number: 1463
-
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Christ M, Störk S, Dörr M, Heppner HJ, Müller C, Wachter R and Riemer U: Trend HF Germany Project. Heart failure epidemiology 2000-2013: Insights from the German federal health monitoring system. Eur J Heart Fail. 18:1009–1018. 2016.PubMed/NCBI View Article : Google Scholar | |
|
DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI and Jemal A: Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA Cancer J Clin. 66:290–308. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S and Chao C: Cardiovascular disease among survivors of adult-onset cancer: A community-based retrospective cohort study. J Clin Oncol. 34:1122–1130. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Choi HM, Park MS and Youn JC: Update on heart failure management and future directions. Korean J Intern Med. 34:11–43. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Swain SM, Whaley FS and Ewer MS: Congestive heart failure in patients treated with doxorubicin: A retrospective analysis of three trials. Cancer. 97:2869–2879. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Saiki H, Petersen IA, Scott CG, Bailey KR, Dunlay SM, Finley RR, Ruddy KJ, Yan E and Redfield MM: Risk of heart failure with preserved ejection fraction in older women after contemporary radiotherapy for breast cancer. Circulation. 135:1388–1396. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 344:783–792. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Quarta CC, Solomon SD, Uraizee I, Kruger J, Longhi S, Ferlito M, Gagliardi C, Milandri A, Rapezzi C and Falk RH: Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis. Circulation. 129:1840–1849. 2014.PubMed/NCBI View Article : Google Scholar | |
|
van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM and van Leeuwen FE: Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. JAMA Intern Med. 175:1007–1017. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Laufer-Perl M, Mor L, Milwidsky A, Derakhshesh M, Amrami N, Moshkovits Y, Arnold J, Topilsky Y, Arbel Y and Rozenbaum Z: Cancer therapeutics-related cardiac dysfunction among patients with active breast cancer: A cardio-oncology registry. Isr Med Assoc J. 22:564–568. 2020.PubMed/NCBI | |
|
Tian Z, Yang Y, Yang Y, Zhang F, Li P, Wang J, Yang J, Zhang P, Yao W and Wang X: High cumulative doxorubicin dose for advanced soft tissue sarcoma. BMC Cancer. 20(1139)2020.PubMed/NCBI View Article : Google Scholar | |
|
Degens J, De Ruysscher D, Houben R, Kietselaer B, Bootsma G, Hendriks L, Huijbers E, Schols A and Dingemans AC: Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study. BMJ Open. 10(e036492)2020.PubMed/NCBI View Article : Google Scholar | |
|
Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, et al: Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 357:2248–2261. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S and Daubert C: REVERSE (REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction) Study Group. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 52:1834–1843. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP, Estes NA III, Foster E, Greenberg H, Higgins SL, et al: Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med. 361:1329–1338. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J III, Gras D, et al: Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 369:1395–1405. 2013.PubMed/NCBI View Article : Google Scholar | |
|
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, et al: Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 371:993–1004. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR and Curiel R: Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 344:493–498. 1994.PubMed/NCBI View Article : Google Scholar | |
|
Bigger JT Jr: Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary artery bypass graft (CABG) patch trial investigators. N Engl J Med. 337:1569–1575. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Kadish A, Dyer A, Daubert JP, Quigg R, Estes NA, Anderson KP, Calkins H, Hoch D, Goldberger J, Shalaby A, et al: Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 350:2151–2158. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA and Swedberg K: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-alternative trial. Lancet. 362:772–776. 2003.PubMed/NCBI View Article : Google Scholar | |
|
McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, Olofsson B, Yusuf S and Pfeffer MA: CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-added trial. Lancet. 362:767–771. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, Arnold JM, Buxton AE, Camm AJ, et al: Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 358:2667–2677. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M and Tognoni G: Gissi-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial. Lancet. 372:1223–1230. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, et al: Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 364:1607–1616. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Bertero E, Canepa M, Maack C and Ameri P: Linking heart failure to cancer: Background evidence and research perspectives. Circulation. 138:735–742. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Meijers WC, Maglione M, Bakker SJL, Oberhuber R, Kieneker LM, de Jong S, Haubner BJ, Nagengast WB, Lyon AR, van der Vegt B, et al: Heart failure stimulates tumor growth by circulating factors. Circulation. 138:678–691. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Bertero E, Ameri P and Maack C: Bidirectional relationship between cancer and heart failure: Old and new issues in cardio-oncology. Card Fail Rev. 5:106–111. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Ausoni S and Azzarello G: Development of cancer in patients with heart failure: How systemic inflammation can lay the groundwork. Front Cardiovasc Med. 7(598384)2020.PubMed/NCBI View Article : Google Scholar | |
|
Tan C, Tasaka H, Yu KP, Murphy ML and Karnofsky DA: Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 20:333–353. 1967.PubMed/NCBI View Article : Google Scholar | |
|
Vandecruys E, Mondelaers V, De Wolf D, Benoit Y and Suys B: Late cardiotoxicity after low dose of anthracycline therapy for acute lymphoblastic leukemia in childhood. J Cancer Surviv. 6:95–101. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Frederick CA, Williams LD, Ughetto G, van der Marel GA, van Boom JH, Rich A and Wang AH: Structural comparison of anticancer drug-DNA complexes: Adriamycin and daunomycin. Biochemistry. 29:2538–2549. 1990.PubMed/NCBI | |
|
Martin E, Thougaard AV, Grauslund M, Jensen PB, Bjorkling F, Hasinoff BB, Tjørnelund J, Sehested M and Jensen LH: Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy. Toxicology. 255:72–79. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF and Yeh ET: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med. 18:1639–1642. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Jones RL: Utility of dexrazoxane for the reduction of anthracycline-induced cardiotoxicity. Expert Rev Cardiovasc Ther. 6:1311–1317. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Hasinoff BB, Patel D and Wu X: The role of topoisomerase IIβ in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane. Cardiovasc Toxicol. 20:312–320. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Abd El-Aziz MA, Othman AI, Amer M and El-Missiry MA: Potential protective role of angiotensin-converting enzyme inhibitors captopril and enalapril against adriamycin-induced acute cardiac and hepatic toxicity in rats. J Appl Toxicol. 21:469–473. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Li M, Sala V, De Santis MC, Cimino J, Cappello P, Pianca N, Di Bona A, Margaria JP, Martini M, Lazzarini E, et al: Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth. Circulation. 138:696–711. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C and Kolesnick R: Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science. 293:293–297. 2001.PubMed/NCBI View Article : Google Scholar | |
|
Orzan F, Brusca A, Conte MR, Presbitero P and Figliomeni MC: Severe coronary artery disease after radiation therapy of the chest and mediastinum: Clinical presentation and treatment. Br Heart J. 69:496–500. 1993.PubMed/NCBI View Article : Google Scholar | |
|
Sag CM, Wolff HA, Neumann K, Opiela MK, Zhang J, Steuer F, Sowa T, Gupta S, Schirmer M, Hünlich M, et al: Ionizing radiation regulates cardiac Ca handling via increased ROS and activated CaMKII. Basic Res Cardiol. 108(385)2013.PubMed/NCBI View Article : Google Scholar | |
|
De Keulenaer GW, Doggen K and Lemmens K: The vulnerability of the heart as a pluricellular paracrine organ: Lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 106:35–46. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Suter TM, Procter M, van Veldhuisen DJ, Muscholl M, Bergh J, Carlomagno C, Perren T, Passalacqua R, Bighin C, Klijn JG, et al: Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol. 25:3859–3865. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Bergers G and Benjamin LE: Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 3:401–410. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Carlsson L, Ronquist G, Elisasson R, Dubois L, Ronquist KG and Larsson A: High concentrations of the angiogenic peptide VEGF-A in seminal fluid and its association to prostasomes. Clin Lab. 62:1515–1520. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Elice F, Jacoub J, Rickles FR, Falanga A and Rodeghiero F: Hemostatic complications of angiogenesis inhibitors in cancer patients. Am J Hematol. 83:862–270. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Cobleigh MA, Langmuir VK, Sledge GW, Miller KD, Haney L, Novotny WF, Reimann JD and Vassel A: A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol. 30 (5 Suppl 16):S117–S124. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Kappers MH, van Esch JH, Sluiter W, Sleijfer S, Danser AH and van den Meiracker AH: Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels. Hypertension. 56:675–681. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Li W, Croce K, Steensma DP, McDermott DF, Ben-Yehuda O and Moslehi J: Vascular and metabolic implications of novel targeted cancer therapies: Focus on kinase inhibitors. J Am Coll Cardiol. 66:1160–1178. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Neves KB, Rios FJ, Jones R, Evans T, Montezano AC and Touyz RM: Microparticles from vascular endothelial growth factor pathway inhibitor-treated cancer patients mediate endothelial cell injury. Cardiovasc Res. 115:978–988. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Maurea N, Coppola C, Piscopo G, Galletta F, Riccio G, Esposito E, De Lorenzo C, De Laurentiis M, Spallarossa P and Mercuro G: Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. J Cardiovasc Med (Hagerstown). 17 (Suppl 1):S19–S26. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Schmidinger M, Zielinski CC, Vogl UM, Bojic A, Bojic M, Schukro C, Ruhsam M, Hejna M and Schmidinger H: Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 26:5204–5212. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 352:2487–2498. 2005.PubMed/NCBI View Article : Google Scholar | |
|
Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, O'Quinn R, Cohen AD, Stadtmauer EA, Ky B and Weiss BM: Carfilzomib-associated cardiovascular adverse events: A systematic review and meta-analysis. JAMA Oncol. 4(e174519)2018.PubMed/NCBI View Article : Google Scholar | |
|
Herrmann J, Wohlert C, Saguner AM, Flores A, Nesbitt LL, Chade A, Lerman LO and Lerman A: Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail. 15:614–623. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y and Hill AP: hERG K(+) channels: Structure, function, and clinical significance. Physiol Rev. 92:1393–1478. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Pier DM, Shehatou GS, Giblett S, Pullar CE, Trezise DJ, Pritchard CA, Challiss RA and Mitcheson JS: Long-term channel block is required to inhibit cellular transformation by human ether-à-go-go-related gene (hERG1) potassium channels. Mol Pharmacol. 86:211–221. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Raschi E, Vasina V, Poluzzi E and De Ponti F: The hERG K+ channel: Target and antitarget strategies in drug development. Pharmacol Res. 57:181–195. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Stansfeld PJ, Sutcliffe MJ and Mitcheson JS: Molecular mechanisms for drug interactions with hERG that cause long QT syndrome. Expert Opin Drug Metab Toxicol. 2:81–94. 2006.PubMed/NCBI View Article : Google Scholar | |
|
He S, Moutaoufik MT, Islam S, Persad A, Wu A, Aly KA, Fonge H, Babu M and Cayabyab FS: HERG channel and cancer: A mechanistic review of carcinogenic processes and therapeutic potential. Biochim Biophys Acta Rev Cancer. 1873(188355)2020.PubMed/NCBI View Article : Google Scholar | |
|
Falk RH, Alexander KM, Liao R and Dorbala S: AL (Light-Chain) cardiac amyloidosis: A review of diagnosis and therapy. J Am Coll Cardiol. 68:1323–1341. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, Cruz M, Berk JL, Plante-Bordeneuve V, Schmidt HHJ and Merlini G: Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J Am Coll Cardiol. 66:2451–2466. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS and Liao R: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res. 94:1008–1010. 2004.PubMed/NCBI View Article : Google Scholar | |
|
Sawyer DB, Siwik DA, Xiao L, Pimentel DR, Singh K and Colucci WS: Role of oxidative stress in myocardial hypertrophy and failure. J Mol Cell Cardiol. 34:379–388. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Lundin L, Norheim I, Landelius J, Oberg K and Theodorsson-Norheim E: Carcinoid heart disease: Relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities. Circulation. 77:264–269. 1988.PubMed/NCBI View Article : Google Scholar | |
|
Modlin IM and Sandor A: An analysis of 8305 cases of carcinoid tumors. Cancer. 79:813–829. 1997.PubMed/NCBI View Article : Google Scholar | |
|
Hassan SA, Banchs J, Iliescu C, Dasari A, Lopez-Mattei J and Yusuf SW: Carcinoid heart disease. Heart. 103:1488–1495. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, Champion C, Durand JB, Gibbs H, Zafarmand AA and Ewer MS: Cardiovascular complications of cancer therapy: Diagnosis, pathogenesis, and management. Circulation. 109:3122–3131. 2004.PubMed/NCBI View Article : Google Scholar | |
|
McKenney AS and Levine RL: Isocitrate dehydrogenase mutations in leukemia. J Clin Invest. 123:3672–3677. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Karlstaedt A, Zhang X, Vitrac H, Harmancey R, Vasquez H, Wang JH, Goodell MA and Taegtmeyer H: Oncometabolite d-2-hydroxyglutarate impairs α-ketoglutarate dehydrogenase and contractile function in rodent heart. Proc Natl Acad Sci USA. 113:10436–10441. 2016.PubMed/NCBI View Article : Google Scholar | |
|
Rinde LB, Småbrekke B, Hald EM, Brodin EE, Njølstad I, Mathiesen EB, Løchen ML, Wilsgaard T, Brækkan SK, Vik A and Hansen JB: Myocardial infarction and future risk of cancer in the general population-the Tromsø study. Eur J Epidemiol. 32:193–201. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Berton G, Cordiano R, Cavuto F, Bagato F, Segafredo B and Pasquinucci M: Neoplastic disease after acute coronary syndrome: Incidence, duration, and features: The ABC-4* study on heart disease. J Cardiovasc Med (Hagerstown). 19:546–553. 2018.PubMed/NCBI View Article : Google Scholar | |
|
de Boer RA, Meijers WC, van der Meer P and van Veldhuisen DJ: Cancer and heart disease: Associations and relations. Eur J Heart Fail. 21:1515–1525. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Arab S, Gramolini AO, Ping P, Kislinger T, Stanley B, van Eyk J, Ouzounian M, MacLennan DH, Emili A and Liu PP: Cardiovascular proteomics: Tools to develop novel biomarkers and potential applications. J Am Coll Cardiol. 48:1733–1741. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Isaac DL: Biomarkers in heart failure management. Curr Opin Cardiol. 23:127–133. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Dewey CM, Spitler KM, Ponce JM, Hall DD and Grueter CE: Cardiac-secreted factors as peripheral metabolic regulators and potential disease biomarkers. J Am Heart Assoc. 5(e003101)2016.PubMed/NCBI View Article : Google Scholar | |
|
Pavo N, Raderer M, Hülsmann M, Scheithauer W, Adlbrecht C, Strunk G, Goliasch G, Gisslinger H, Steger GG, Hejna M, et al: Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality. Heart. 101:1874–1880. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Tuñón J, Higueras J, Tarín N, Cristóbal C, Lorenzo Ó, Blanco-Colio L, Martín-Ventura JL, Huelmos A, Alonso J, Aceña Á, et al: N-terminal pro-brain natriuretic peptide is associated with a future diagnosis of cancer in patients with coronary artery disease. PLoS One. 10(e0126741)2015.PubMed/NCBI View Article : Google Scholar | |
|
de Boer RA, Daniels LB, Maisel AS and Januzzi JL Jr: State of the Art: Newer biomarkers in heart failure. Eur J Heart Fail. 17:559–569. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Hartupee J and Mann DL: Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol. 14:30–38. 2017.PubMed/NCBI View Article : Google Scholar | |
|
George AJ, Thomas WG and Hannan RD: The renin-angiotensin system and cancer: Old dog, new tricks. Nat Rev Cancer. 10:745–759. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Ino K, Shibata K, Kajiyama H, Yamamoto E, Nagasaka T, Nawa A, Nomura S and Kikkawa F: Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br J Cancer. 94:552–560. 2006.PubMed/NCBI View Article : Google Scholar | |
|
Catarata MJ, Ribeiro R, Oliveira MJ, Robalo Cordeiro C and Medeiros R: Renin-angiotensin system in lung tumor and microenvironment interactions. Cancers (Basel). 12(1457)2020.PubMed/NCBI View Article : Google Scholar | |
|
Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL and Robertson JW: Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 352:179–184. 1998.PubMed/NCBI View Article : Google Scholar | |
|
Werner CM and Böhm M: The therapeutic role of RAS blockade in chronic heart failure. Ther Adv Cardiovasc Dis. 2:167–177. 2008.PubMed/NCBI View Article : Google Scholar | |
|
Reuter S, Gupta SC, Chaturvedi MM and Aggarwal BB: Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med. 49:1603–1616. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Takimoto E and Kass DA: Role of oxidative stress in cardiac hypertrophy and remodeling. Hypertension. 49:241–248. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Maiuri MC and Kroemer G: Essential role for oxidative phosphorylation in cancer progression. Cell Metab. 21:11–12. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Diniz YS, Cicogna AC, Padovani CR, Silva MD, Faine LA, Galhardi CM, Rodrigues HG and Novelli EL: Dietary restriction and fibre supplementation: Oxidative stress and metabolic shifting for cardiac health. Can J Physiol Pharmacol. 81:1042–1048. 2003.PubMed/NCBI View Article : Google Scholar | |
|
Aune D, Chan DS, Greenwood DC, Vieira AR, Rosenblatt DA, Vieira R and Norat T: Dietary fiber and breast cancer risk: A systematic review and meta-analysis of prospective studies. Ann Oncol. 23:1394–1402. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS and Stanley WC: Myocardial fatty acid metabolism in health and disease. Physiol Rev. 90:207–258. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, et al: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell. 11:37–51. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Mann DL: Innate immunity and the failing heart: The cytokine hypothesis revisited. Circ Res. 116:1254–1268. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T and Glynn RJ: CANTOS Trial Group. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: A secondary analysis from the CANTOS randomised controlled trial. Lancet. 391:319–328. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P and Glynn RJ: CANTOS Trial Group. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: Exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 390:1833–1842. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Swann JB and Smyth MJ: Immune surveillance of tumors. J Clin Invest. 117:1137–1146. 2007.PubMed/NCBI View Article : Google Scholar | |
|
Zhang Y, Bauersachs J and Langer HF: Immune mechanisms in heart failure. Eur J Heart Fail. 19:1379–1389. 2017.PubMed/NCBI View Article : Google Scholar | |
|
Epelman S, Liu PP and Mann DL: Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol. 15:117–129. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Frantz S, Falcao-Pires I, Balligand JL, Bauersachs J, Brutsaert D, Ciccarelli M, Dawson D, de Windt LJ, Giacca M, Hamdani N, et al: The innate immune system in chronic cardiomyopathy: A European society of cardiology (ESC) scientific statement from the working group on myocardial function of the ESC. Eur J Heart Fail. 20:445–459. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Stakos DA, Kambas K, Konstantinidis T, Mitroulis I, Apostolidou E, Arelaki S, Tsironidou V, Giatromanolaki A, Skendros P, Konstantinides S and Ritis K: Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction. Eur Heart J. 36:1405–1414. 2015.PubMed/NCBI View Article : Google Scholar | |
|
Frangogiannis NG, Smith CW and Entman ML: The inflammatory response in myocardial infarction. Cardiovasc Res. 53:31–47. 2002.PubMed/NCBI View Article : Google Scholar | |
|
Sun K, Li YY and Jin J: A double-edged sword of immuno-microenvironment in cardiac homeostasis and injury repair. Signal Transduct Target Ther. 6(79)2021.PubMed/NCBI View Article : Google Scholar | |
|
Oktay AA, Rich JD and Shah SJ: The emerging epidemic of heart failure with preserved ejection fraction. Curr Heart Fail Rep. 10:401–410. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Pandya PH, Murray ME, Pollok KE and Renbarger JL: The immune system in cancer pathogenesis: Potential therapeutic approaches. J Immunol Res. 2016(4273943)2016.PubMed/NCBI View Article : Google Scholar | |
|
Wei J, Galaviz KI, Kowalski AJ, Magee MJ, Haw JS, Narayan KMV and Ali MK: Comparison of cardiovascular events among users of different classes of antihypertension medications: A systematic review and network meta-analysis. JAMA Netw Open. 3(e1921618)2020.PubMed/NCBI View Article : Google Scholar | |
|
Sipahi I, Debanne SM, Rowland DY, Simon DI and Fang JC: Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol. 11:627–636. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C and Messerli FH: Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12:65–82. 2011.PubMed/NCBI View Article : Google Scholar | |
|
ARB Trialists Collaboration. Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J Hypertens. 29:623–635. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Chang CH, Lin JW, Wu LC and Lai MS: Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: A nationwide case-control study. J Clin Oncol. 29:3001–3007. 2011.PubMed/NCBI View Article : Google Scholar | |
|
McNeil JJ, Gibbs P, Orchard SG, Lockery JE, Bernstein WB, Cao Y, Ford L, Haydon A, Kirpach B, Macrae F, et al: Effect of aspirin on cancer incidence and mortality in older adults. J Natl Cancer Inst. 113:258–265. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Falix FA, Aronson DC, Lamers WH and Gaemers IC: Possible roles of DLK1 in the Notch pathway during development and disease. Biochim Biophys Acta. 1822:988–995. 2012.PubMed/NCBI View Article : Google Scholar | |
|
Rodriguez P, Sassi Y, Troncone L, Benard L, Ishikawa K, Gordon RE, Lamas S, Laborda J, Hajjar RJ and Lebeche D: Deletion of delta-like 1 homologue accelerates fibroblast-myofibroblast differentiation and induces myocardial fibrosis. Eur Heart J. 40:967–978. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Akiyama J, Okamoto R, Iwasaki M, Zheng X, Yui S, Tsuchiya K, Nakamura T and Watanabe M: Delta-like 1 expression promotes goblet cell differentiation in Notch-inactivated human colonic epithelial cells. Biochem Biophys Res Commun. 393:662–667. 2010.PubMed/NCBI View Article : Google Scholar | |
|
Wei Y, Shao J, Wang Y, Shen H, Yu S, Zhang J and Yin L: Hsa-miR-370 inhibited P-selectin-induced cell adhesion in human colon adenocarcinoma cells. Mol Cell Biochem. 450:159–166. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Wu XS, Wang XA, Wu WG, Hu YP, Li ML, Ding Q, Weng H, Shu YJ, Liu TY, Jiang L, et al: MALAT1 promotes the proliferation and metastasis of gallbladder cancer cells by activating the ERK/MAPK pathway. Cancer Biol Ther. 15:806–814. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Liu JY, Yao J, Li XM, Song YC, Wang XQ, Li YJ, Yan B and Jiang Q: Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus. Cell Death Dis. 5(e1506)2014.PubMed/NCBI View Article : Google Scholar | |
|
Gast M, Rauch BH, Nakagawa S, Haghikia A, Jasina A, Haas J, Nath N, Jensen L, Stroux A, Böhm A, et al: Immune system-mediated atherosclerosis caused by deficiency of long non-coding RNA MALAT1 in ApoE-/-mice. Cardiovasc Res. 115:302–314. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Cremer S, Michalik KM, Fischer A, Pfisterer L, Jaé N, Winter C, Boon RA, Muhly-Reinholz M, John D, Uchida S, et al: Hematopoietic deficiency of the long noncoding RNA MALAT1 promotes atherosclerosis and plaque inflammation. Circulation. 139:1320–1334. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Li X, Li Y, Zhang T, Xiong X, Liu N, Pang B, Ruan Y, Gao Y, Shang H and Xing Y: Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials. Pharmacol Res. 151(104577)2020.PubMed/NCBI View Article : Google Scholar | |
|
Totzeck M, Mincu RI, Heusch G and Rassaf T: Heart failure from cancer therapy: Can we prevent it? ESC Heart Fail. 6:856–862. 2019.PubMed/NCBI View Article : Google Scholar | |
|
Kollárová-Brázdová P, Jirkovská A, Karabanovich G, Pokorná Z, Bavlovič Piskáčková H, Jirkovský E, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, et al: Investigation of structure-activity relationships of dexrazoxane analogs reveals topoisomerase IIβ interaction as a prerequisite for effective protection against anthracycline cardiotoxicity. J Pharmacol Exp Ther. 373:402–415. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Chang WT, Lin YW, Ho CH, Chen ZC, Liu PY and Shih JY: Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients. Arch Toxicol. 95:659–671. 2021.PubMed/NCBI View Article : Google Scholar | |
|
Fitzgerald MD, Tanaka H, Tran ZV and Seals DR: Age-related declines in maximal aerobic capacity in regularly exercising vs sedentary women: A meta-analysis. J Appl Physiol (1985). 83:160–165. 1997.PubMed/NCBI View Article : Google Scholar | |
|
MacVicar MG, Winningham ML and Nickel JL: Effects of aerobic interval training on cancer patients' functional capacity. Nurs Res. 38:348–351. 1989.PubMed/NCBI | |
|
Jones LW, Fels DR, West M, Allen JD, Broadwater G, Barry WT, Wilke LG, Masko E, Douglas PS, Dash RC, et al: Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy. Cancer Prev Res (Phila). 6:925–937. 2013.PubMed/NCBI View Article : Google Scholar | |
|
Courneya KS, Sellar CM, Stevinson C, McNeely ML, Peddle CJ, Friedenreich CM, Tankel K, Basi S, Chua N, Mazurek A and Reiman T: Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol. 27:4605–4612. 2009.PubMed/NCBI View Article : Google Scholar | |
|
Jones LW, Douglas PS, Khouri MG, Mackey JR, Wojdyla D, Kraus WE, Whellan DJ and O'Connor CM: Safety and efficacy of aerobic training in patients with cancer who have heart failure: An analysis of the HF-ACTION randomized trial. J Clin Oncol. 32:2496–2502. 2014.PubMed/NCBI View Article : Google Scholar | |
|
Hughes DC, Lenihan DJ, Harrison CA and Basen-Engquist KM: Exercise intervention for cancer survivors with heart failure: Two case reports. J Exerc Sci Fit. 9:65–73. 2011.PubMed/NCBI View Article : Google Scholar | |
|
Maginador G, Lixandrão ME, Bortolozo HI, Vechin FC, Sarian LO, Derchain S, Telles GD, Zopf E, Ugrinowitsch C and Conceição MS: Aerobic exercise-induced changes in cardiorespiratory fitness in breast cancer patients receiving chemotherapy: A systematic review and meta-analysis. Cancers (Basel). 12(2240)2020.PubMed/NCBI View Article : Google Scholar | |
|
Rochette L, Meloux A, Zeller M, Cottin Y and Vergely C: Role of humanin, a mitochondrial-derived peptide, in cardiovascular disorders. Arch Cardiovasc Dis. 113:564–571. 2020.PubMed/NCBI View Article : Google Scholar | |
|
Cai H, Liu Y, Men H and Zheng Y: Protective mechanism of humanin against oxidative stress in aging-related cardiovascular diseases. Front Endocrinol (Lausanne). 12(683151)2021.PubMed/NCBI View Article : Google Scholar | |
|
Thummasorn S, Shinlapawittayatorn K, Khamseekaew J, Jaiwongkam T, Chattipakorn SC and Chattipakorn N: Humanin directly protects cardiac mitochondria against dysfunction initiated by oxidative stress by decreasing complex I activity. Mitochondrion. 38:31–40. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Qin Q, Mehta H, Yen K, Navarrete G, Brandhorst S, Wan J, Delrio S, Zhang X, Lerman LO, Cohen P and Lerman A: Chronic treatment with the mitochondrial peptide humanin prevents age-related myocardial fibrosis in mice. Am J Physiol Heart Circ Physiol. 315:H1127–H1136. 2018.PubMed/NCBI View Article : Google Scholar | |
|
Lue Y, Swerdloff R, Wan J, Xiao J, French S, Atienza V, Canela V, Bruhn KW, Stone B, Jia Y, et al: The potent humanin analogue (HNG) protects germ cells and leucocytes while enhancing chemotherapy-induced suppression of cancer metastases in male mice. Endocrinology. 156:4511–4521. 2015.PubMed/NCBI View Article : Google Scholar |
